Engineered telomere degradation models dyskeratosis congenita

Genes and Development

Volumn 22, Issue 13, 2008, Pages 1773-1785

  Hockemeyer, Dirk ^a,d   Palm, Wilhelm ^a,e   Wang, Richard C ^b   Couto, Suzana S ^c   De Lange, Titia ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS AT DALLAS   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH   (United States)

^e MAX PLANCK INSTITUTE OF MOLECULAR CELL BIOLOGY AND GENETICS   (Germany)

Author keywords

Bone marrow failure; Dyskeratosis congenita; POT1; Shelterin; Telomerase; Telomere

Indexed keywords

PROTEIN; PROTEIN POT1B; SHELTERIN; TELOMERASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW DEPRESSION; CONTROLLED STUDY; DYSKERATOSIS CONGENITA; ENZYME ACTIVITY; GENETIC ENGINEERING; GENOTYPE PHENOTYPE CORRELATION; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; MOUSE; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; TELOMERE;

ANIMALS; BONE MARROW; DISEASE MODELS, ANIMAL; DNA-BINDING PROTEINS; DYSKERATOSIS CONGENITA; LONGEVITY; MICE; PHENOTYPE; SKIN PIGMENTATION; TELOMERASE; TELOMERE;

MUS;

EID: 46249089163     PISSN: 08909369     EISSN: 15495477     Source Type: Journal    
DOI: 10.1101/gad.1679208     Document Type: Article

References (61)

1. Allsopp, R.C., Morin, G.B., DePinho, R., Harley, C.B., and Weissman, I.L. 2003. Telomerase is required to slow telomere shortening and extend replicative lifespan of HSC during serial transplantation. Blood 102: 517-520.
2. Alter, B.P., Baerlocher, G.M., Savage, S.A., Chanock, S.J., Weksler, B.B., Willner, J.P., Peters, J.A., Giri, N., and Lansdorp, P.M. 2007. Very short telomere length by flow fluorescence in situ hybridization identifies patients with dyskeratosis congenita. Blood 110: 1439-1447.
3. Armanios, M., Chen, J.L., Chang, Y.P., Brodsky, R.A., Hawkins, A., Griffin, C.A., Eshleman, J.R., Cohen, A.R., Chakravarti, A., Hamosh, A., et al. 2005. Haploinsufficiency of telomerase reverse transcriptase leads to anticipation in autosomal dominant dyskeratosis congenita. Proc. Natl. Acad. Sci. 102: 15960-15964.
4. Armanios, M.Y., Chen, J.J., Cogan, J.D., Alder, J.K., Ingersoll, R.G., Markin, C., Lawson, W.E., Xie, M., Vulto, I., Phillips, J.A.R., et al. 2007. Telomerase mutations in families with idiopathic pulmonary fibrosis. N. Engl. J. Med. 356: 1317-1326.
5. Barnett, M.A., Buckle, V.J., Evans, E.P., Porter, A.C., Rout, D., Smith, A.G., and Brown, W.R. 1993. Telomere directed fragmentation of mammalian chromosomes. Nucleic Acids Res. 21: 27-36.
6. Baumann, P. and Cech, T.R. 2001. Pot1, the putative telomere end-binding protein in fission yeast and humans. Science 292: 1171-1175.
7. Blasco, M.A., Lee, H.W., Hande, M.P., Samper, E., Lansdorp, P.M., DePinho, R.A., and Greider, C.W. 1997. Telomere shortening and tumor formation by mouse cells lacking telomerase RNA. Cell 91: 25-34.
8. Byers, H.R., Maheshwary, S., Amodeo, D.M., and Dykstra, S.G. 2003. Role of cytoplasmic dynein in perinuclear aggregation of phagocytosed melanosomes and supranuclear melanin cap formation in human keratinocytes. J. Invest. Dermatol. 121: 813-820.
9. Cerone, M.A., Ward, R.J., Londono-Vallejo, J.A., and Autexier, C. 2005. Telomerase RNA mutated in autosomal dyskeratosis congenita reconstitutes a weakly active telomerase enzyme defective in telomere elongation. Cell Cycle 4: 585-589.
10. Cohen, S., Me, G., Lovrecz, G.O., Bache, N., Robinson, P.J., and Reddel, R.R. 2007. Protein composition of catalytically active human telomerase from immortal cells. Science 315: 1850-1853.
11. Cristofari, G. and Lingner, J. 2006. Telomere length homeostasis requires that telomerase levels are limiting. EMBO J. 25: 565-574.
12. Cui, R., Widlund, H.R., Feige, E., Lin, J.Y., Wilensky, D.L., Igras, V.E., D'Orazio, J., Fung, C.Y., Schanbacher, C.F., Granter, S.R., et al. 2007. Central role of p53 in the suntan response and pathologic hyperpigmentation. Cell 128: 853-864.
13. de Lange, T. 2005. Shelterin: The protein complex that shapes and safeguards human telomeres. Genes & Dev. 19: 2100-2110.
14. Dokal, I. and Vulliamy, T. 2005. Telomerase deficiency and human disease. In Telomeres (eds. T. de Lange et al.), pp. 139-162. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
15. Erdmann, N., Liu, Y., and Harrington, L. 2004. Distinct dosage requirements for the maintenance of long and short telomeres in mTert heterozygous mice. Proc. Natl. Acad. Sci. 101: 6080-6085.
16. Gates, R.R. and Zimmermann, A.A. 1953. Comparison of skin color with melanin content. J. Invest. Dermatol. 21: 339-348.
17. Gavrieli, Y., Sherman, Y., and Ben-Sasson, S.A. 1992. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J. Cell Biol. 119: 493-501.
18. Gottschling, D.E. and Zakian, V.A. 1986. Telomere proteins: Specific recognition and protection of the natural termini of Oxytricha macronuclear DNA. Cell 47: 195-205.
19. Griffith, J.D., Comeau, L., Rosenfield, S., Stansel, R.M., Bianchi, A., Moss, H., and de Lange, T. 1999. Mammalian telomeres end in a large duplex loop. Cell 97: 503-514.
20. Hao, L.Y., Armanios, M., Strong, M.A., Karim, B., Feldser, D.M., Huso, D., and Greider, C.W. 2005. Short telomeres, even in the presence of telomerase, limit tissue renewal capacity. Cell 123: 1121-1131.
21. Hathcock, K.S., Hemann, M.T., Opperman, K.K., Strong, M.A., Greider, C.W., and Hodes, R.J. 2002. Haploinsufficiency of mTR results in defects in telomere elongation. Proc. Natl. Acad. Sci. 99: 3591-3596.
22. Heiss, N.S., Knight, S.W., Vulliamy, T.J., Klauck, S.M., Wiemann, S., Mason, P.J., Poustka, A., and Dokal, I. 1998. X-linked dyskeratosis congenita is caused by mutations in a highly conserved gene with putative nucleolar functions. Nat. Genet. 19: 32-38.
23. Hockemeyer, D., Daniels, J.P., Takai, H., and de Lange, T. 2006. Recent expansion of the telomeric complex in rodents: Two distinct POT1 proteins protect mouse telomeres. Cell 126: 63-77.
24. Hockemeyer, D., Palm, W., Else, T., Daniels, J.P., Takai, K.K., Ye, J.Z., Keegan, C.E., de Lange, T., and Hammer, G.D. 2007. Telomere protection by mammalian POT1 requires interaction with TPP1. Nat. Struct. Mol. Biol. 14: 754-761.
25. Jacobs, J.J. and de Lange, T. 2004. Significant role for p16(INK4a) in p53-independent telomere-directed senescence. Curr. Biol. 14: 2302-2308.
26. Lazzerini Denchi, E. and de Lange, T. 2007. Protection of telomeres through independent control of ATM and ATR by TRF2 and POT1. Nature 448: 1068-1071.
27. Lee, H.W., Blasco, M.A., Gottlieb, G.J., Horner 2nd, J.W., Greider, C.W., and DePinho, R.A. 1998. Essential role of mouse telomerase in highly proliferative organs. Nature 392: 569-574.
28. Lingner, J., Cooper, J.P., and Cech, T.R. 1995. Telomerase and DNA end replication: No longer a lagging strand problem? Science 269: 1533-1534.
29. Liu, Y., Snow, B.E., Hande, M.P., Yeung, D., Erdmann, N.J., Wakeham, A., Itie, A., Siderovski, D.P., Lansdorp, P.M., Robinson, M.O., et al. 2000. The telomerase reverse transcriptase is limiting and necessary for telomerase function in vivo. Curr. Biol. 10: 1459-1462.
30. Loayza, D. and de Lange, T. 2003. POT1 as a terminal transducer of TRF1 telomere length control. Nature 424: 1013-1018.
31. Makarov, V.L., Hirose, Y., and Langmore, J.P. 1997. Long G tails at both ends of human chromosomes suggest a C strand degradation mechanism for telomere shortening. Cell 88: 657-666.
32. Maringele, L. and Lydall, D. 2002. EXO1-dependent single-stranded DNA at telomeres activates subsets of DNA damage and spindle checkpoint pathways in budding yeast yku70Δ mutants. Genes & Dev. 16: 1919-1933.
33. Marrone, A., Stevens, D., Vulliamy, T., Dokal, I., and Mason, P.J. 2004. Heterozygous telomerase RNA mutations found in dyskeratosis congenita and aplastic anemia reduce telomerase activity via haploinsufficiency. Blood 104: 3936-3942.
34. Marrone, A., Walne, A., Tamary, H., Masunari, Y., Kirwan, M., Beswick, R., Vulliamy, T., and Dokal, I. 2007. Telomerase reverse-transcriptase homozygous mutations in autosomal recessive dyskeratosis congenita and Hoyeraal-Hreidarsson syndrome. Blood 110: 4198-4205.
35. McChesney, P.A., Aisner, D.L., Frank, B.C., Wright, W.E., and Shay, J.W. 2000. Telomere dynamics in cells with introduced telomerase: A rapid assay for telomerase activity on telomeres. Mol. Cell Biol. Res. Commun. 3: 312-318.
36. Meier, U.T. 2006. How a single protein complex accommodates many different H/ACA RNAs. Trends Biochem. Sci. 31: 311-315.
37. Mitchell, J.R., Wood, E., and Collins, K. 1999. A telomerase component is defective in the human disease dyskeratosis congenita. Nature 402: 551-555.
38. Mochizuki, Y., He, J., Kulkarni, S., Bessler, M., and Mason, P.J. 2004. Mouse dyskerin mutations affect accumulation of telomerase RNA and small nucleolar RNA, telomerase activity, and ribosomal RNA processing. Proc. Natl. Acad. Sci. 101: 10756-10761.
39. Nikaido, R., Haruyama, T., Watanabe, Y., Iwata, H., Iida, M., Sugimura, H., Yamada, N., and Ishikawa, F. 1999. Presence of telomeric G-strand tails in the telomerase catalytic subunit TERT knockout mice. Genes Cells 4: 563-572.
40. Palm, W. and de Lange, T. 2008. How shelterin protects mammalian telomeres. Annu. Rev. Genet. (in press).
41. Prowse, K.R. and Greider, C.W. 1995. Developmental and tissue-specific regulation of mouse telomerase and telomere length. Proc. Natl. Acad. Sci. 92: 4818-4822.
42. Rudolph, K.L., Chang, S., Lee, H.W., Blasco, M., Gottlieb, G.J., Greider, C., and DePinho, R.A. 1999. Longevity, stress response, and cancer in aging telomerase-deficient mice. Cell 96: 701-712.
43. Rudolph, K.L., Chang, S., Millard, M., Schreiber-Agus, N., and DePinho, R.A. 2000. Inhibition of experimental liver cirrhosis in mice by telomerase gene delivery. Science 287: 1253-1258.
44. Ruggero, D., Grisendi, S., Piazza, F., Rego, E., Mari, F., Rao, P.H., Cordon-Cardo, C., and Pandolfi, P.P. 2003. Dyskeratosis congenita and cancer in mice deficient in ribosomal RNA modification. Science 299: 259-262.
45. Sarin, K.Y., Cheung, P., Gilison, D., Lee, E., Tennen, R.I., Wang, E., Artandi, M.K., Oro, A.E., and Artandi, S.E. 2005. Conditional telomerase induction causes proliferation of hair follicle stem cells. Nature 436: 1048-1052.
46. Savage, S.A., Giri, N., Baerlocher, G.M., Orr, N., Lansdorp, P.M., and Alter, B.P. 2008. TINF2, a component of the shelterin telomere protection complex, is mutated in dyskeratosis congenita. Am. J. Hum. Genet. 82: 501-509.
47. Smogorzewska, A. and de Lange, T. 2002. Different telomere damage signaling pathways in human and mouse cells. EMBO J. 21: 4338-4348.
48. Stewart, S.A., Hahn, W.C., O'Connor, B.F., Banner, E.N., Lundberg, A.S., Modha, P., Mizuno, H., Brooks, M.W., Fleming, M., Zimonjic, D.B., et al. 2002. Telomerase contributes to tumorigenesis by a telomere length-independent mechanism. Proc. Natl. Acad. Sci. 99: 12606-12611.
49. van Steensel, B., Smogorzewska, A., and de Lange, T. 1998. TRF2 protects human telomeres from end-to-end fusions. Cell 92: 401-413.
50. Vaziri, H., Dragowska, W., Allsopp, R.C., Thomas, T.E., Harley, C.B., and Lansdorp, P.M. 1994. Evidence for a mitotic clock in human hematopoietic stem cells: Loss of telomeric DNA with age. Proc. Natl. Acad. Sci. 91: 9857-9860.
51. Vulliamy, T., Marrone, A., Goldman, F., Dearlove, A., Bessler, M., Mason, P.J., and Dokal, I. 2001. The RNA component of telomerase is mutated in autosomal dominant dyskeratosis congenita. Nature 413: 432-435.
52. Vulliamy, T., Marrone, A., Szydlo, R., Walne, A., Mason, P.J., and Dokal, I. 2004. Disease anticipation is associated with progressive telomere shortening in families with dyskeratosis congenita due to mutations in TERC. Nat. Genet. 36: 447-449.
53. Walne, A.J., Vulliamy, T., Marrone, A., Beswick, R., Kirwan, M., Masunari, Y., Al-Qurashi, F.H., Aljurf, M., and Dokal, I. 2007. Genetic heterogeneity in autosomal recessive dyskeratosis congenita with one subtype due to mutations in the telomerase-associated protein NOP10. Hum. Mol. Genet. 16: 1619-1629.
54. Westin, E.R., Chavez, E., Lee, K.M., Gourronc, F.A., Riley, S., Lansdorp, P.M., Goldman, F.D., and Klingelhutz, A.J. 2007. Telomere restoration and extension of proliferative lifespan in dyskeratosis congenita fibroblasts. Aging Cell 6: 383-394.
55. Wong, J.M. and Collins, K. 2006. Telomerase RNA level limits telomere maintenance in X-linked dyskeratosis congenita. Genes & Dev. 20: 2848-2858.
56. Wong, J.M., Kyasa, M.J., Hutchins, L., and Collins, K. 2004. Telomerase RNA deficiency in peripheral blood mononuclear cells in X-linked dyskeratosis congenita. Hum. Genet. 115: 448-455.
57. Wu, L., Multani, A.S., He, H., Cosme-Blanco, W., Deng, Y., Deng, J.M., Bachilo, O., Pathak, S., Tahara, H., Bailey, S.M., et al. 2006. Pot1 deficiency initiates DNA damage checkpoint activation and aberrant homologous recombination at telomeres. Cell 126: 49-62.
58. Yaghmai, R., Kimyai-Asadi, A., Rostamiani, K., Heiss, N.S., Poustka, A., Eyaid, W., Bodurtha, J., Nousari, H.C., Hamosh, A., and Metzenberg, A. 2000. Overlap of dyskeratosis congenita with the Hoyeraal-Hreidarsson syndrome. J. Pediatr. 136: 390-393.
59. Yamaguchi, H., Baerlocher, G.M., Lansdorp, P.M., Chanock, S.J., Nunez, O., Sloand, E., and Young, N.S. 2003. Mutations of the human telomerase RNA gene (TERC) in aplastic anemia and myelodysplastic syndrome. Blood 102: 916-918.
60. Yamaguchi, H., Calado, R.T., Ly, H., Kajigaya, S., Baerlocher, G.M., Chanock, S.J., Lansdorp, P.M., and Young, N.S. 2005. Mutations in TERT, the gene for telomerase reverse transcriptase, in aplastic anemia. N. Engl. J. Med. 352: 1413-1424.
61. Zhu, J., Wang, H., Bishop, J.M., and Blackburn, E.H. 1999. Telomerase extends the lifespan of virus-transformed human cells without net telomere lengthening. Proc. Natl. Acad. Sci. 96: 3723-3728.